AC Immune has been granted a patent for novel compounds that can be used to treat disorders related to Tau protein aggregates, including Alzheimer’s disease. The patent includes a specific compound formula (I). GlobalData’s report on AC Immune gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AC Immune, Neuro-degenerative receptor binding drug compositions was a key innovation area identified from patents. AC Immune's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Novel compounds for treating tau protein-related disorders
A recently granted patent (Publication Number: US11814378B2) discloses a compound of formula (I) and its various derivatives, including compounds of formulas (Ia), (Ib), and (Ic). The patent also covers the use of these compounds in pharmaceutical compositions for treating disorders associated with Tau protein aggregates. The disclosed method involves administering the compound to subjects suffering from conditions like Alzheimer's disease, Parkinson's disease, multiple sclerosis, and various other neurodegenerative disorders linked to Tau protein aggregation. Additionally, the patent includes claims for methods of decreasing Tau aggregation, preventing the formation of Tau aggregates, interfering intracellularly with Tau aggregates, reducing Tau misfolding and hyperphosphorylation, and reducing neuroinflammatory markers in subjects with Tau-related disorders.
Furthermore, the patent extends to the use of specific compounds or their pharmaceutically acceptable salts for treating disorders associated with Tau protein aggregates. The disclosed method involves administering these compounds to subjects in need, with a focus on conditions like Alzheimer's disease and progressive supranuclear palsy. The patent also covers methods for decreasing Tau aggregation, interfering with Tau aggregates intracellularly, and reducing neuroinflammatory markers in individuals suffering from Tau-related disorders. Overall, the patent provides a comprehensive framework for utilizing the disclosed compounds in the development of therapeutic interventions for a wide range of neurodegenerative conditions associated with Tau protein aggregation.
To know more about GlobalData’s detailed insights on AC Immune, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
